Evidence map›Paper›PMID 34572086›Full record

ArticleCells2021

Chenodeoxycholic Acid Pharmacology in Biotechnology and Transplantable Pharmaceutical Applications for Tissue Delivery: An Acute Preclinical Study.

Armin Mooranian, Corina Mihaela Ionescu, Susbin Raj Wagle, Bozica Kovacevic, Daniel Walker, Melissa Jones, Jacqueline Chester, Edan Johnston, Maja Danic, Momir Mikov and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Armin MooranianBiotechnology and Drug Development Research Laboratory, Curtin Medical School, Health Innovation Research Institute, Curtin University, Perth 6102, Australia.
Corina Mihaela IonescuBiotechnology and Drug Development Research Laboratory, Curtin Medical School, Health Innovation Research Institute, Curtin University, Perth 6102, Australia.ORCID 0000-0002-8966-0448
Susbin Raj WagleBiotechnology and Drug Development Research Laboratory, Curtin Medical School, Health Innovation Research Institute, Curtin University, Perth 6102, Australia.ORCID 0000-0001-9867-8896
Bozica KovacevicBiotechnology and Drug Development Research Laboratory, Curtin Medical School, Health Innovation Research Institute, Curtin University, Perth 6102, Australia.ORCID 0000-0002-9359-7840
Daniel WalkerBiotechnology and Drug Development Research Laboratory, Curtin Medical School, Health Innovation Research Institute, Curtin University, Perth 6102, Australia.ORCID 0000-0002-1332-4392
Melissa JonesBiotechnology and Drug Development Research Laboratory, Curtin Medical School, Health Innovation Research Institute, Curtin University, Perth 6102, Australia.ORCID 0000-0002-2771-1158
Jacqueline ChesterBiotechnology and Drug Development Research Laboratory, Curtin Medical School, Health Innovation Research Institute, Curtin University, Perth 6102, Australia.ORCID 0000-0002-5528-2370
Edan JohnstonBiotechnology and Drug Development Research Laboratory, Curtin Medical School, Health Innovation Research Institute, Curtin University, Perth 6102, Australia.
Maja DanicDepartment of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, 21101 Novi Sad, Serbia.ORCID 0000-0002-7785-0666
Momir MikovDepartment of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, 21101 Novi Sad, Serbia.
Crispin DassCurtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Perth 6102, Australia.ORCID 0000-0001-7087-7957
Hani Al-SalamiBiotechnology and Drug Development Research Laboratory, Curtin Medical School, Health Innovation Research Institute, Curtin University, Perth 6102, Australia.ORCID 0000-0003-0049-6969
Curtin University · AUUniversity of Novi Sad · RS

Funding

Beijing Nat-Med Biotechnology Co. Ltd N/ACurtin Faculty ORS-WAHAI Consortium and the Australian National Health and Medical Research APP9000597European Union Horizon 2020 research project and innovation program under the Marie Skłodowska-Curie Grant Agreement 872370
6 · The paper itself

Abstract

introductionPrimary bile acids (PBAs) are produced and released into human gut as a result of cholesterol catabolism in the liver. A predominant PBA is chenodeoxycholic acid (CDCA), which in a recent study in our laboratory, showed significant excipient-stabilizing effects on microcapsules carrying insulinoma β-cells, in vitro, resulting in improved cell functions and insulin release, in the hyperglycemic state. Hence, this study aimed to investigate the applications of CDCA in bio-encapsulation and transplantation of primary healthy viable islets, preclinically, in type 1 diabetes.

methodsHealthy islets were harvested from balb/c mice, encapsulated in CDCA microcapsules, and transplanted into the epididymal tissues of 6 syngeneic diabetic mice, post diabetes confirmation. Pre-transplantation, the microcapsules' morphology, size, CDCA-deep layer distribution, and physical features such as swelling ratio and mechanical strength were analyzed. Post-transplantation, animals' weight, bile acids', and proinflammatory biomarkers' concentrations were analyzed. The control group was diabetic mice that were transplanted encapsulated islets (without PBA). RESULTS AND

conclusionIslet encapsulation by PBA microcapsules did not compromise the microcapsules' morphology or features. Furthermore, the PBA-graft performed better in terms of glycemic control and resulted in modulation of the bile acid profile in the brain. This is suggestive that the improved glycemic control was mediated via brain-related effects. However, the improvement in graft insulin delivery and glycemic control was short-term.

Indexed as

AnimalsBiotechnologyCapsulesChenodeoxycholic AcidDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Gastrointestinal AgentsInsulin-Secreting CellsIslets of Langerhans TransplantationMaleMiceMice, Inbred BALB CCapsulesChenodeoxycholic AcidGastrointestinal Agentschenodeoxycholic acidprimary human bile acidtransplantationtype 1 diabetes

Identifiers

PMID34572086
PMCPMC8472107
OpenAlexW3201637747

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.